Source comparison
CJC-1295 no DAC vs Ipamorelin: Dosing Drives Monthly Cost
The peptide combination works synergistically, but their dosing requirements differ enough to materially impact monthly budgets. CJC-1295 no DAC (modified growth hormone-releasing hormone) has a half-life of approximately 7 days, allowing for less frequent adm
This comparison does not assign a generated winner or score.
- The peptide combination works synergistically, but their dosing requirements differ enough to materially impact monthly budgets. CJC-1295 no DAC (modified growth hormone-releasing hormone) has a half-life of approximately 7 days, allowing for less frequent administration. The standard research protocol uses 100mcg per injection, three times weekly. A 5mg vial contains 5,000mcg total, yielding 50 doses at 100mcg each. At three doses weekly, one vial lasts approximately 16–17 weeks.
- Ipamorelin (growth hormone secretagogue) has a significantly shorter half-life of roughly 2 hours, requiring more frequent dosing to maintain elevated IGF-1 levels. Standard protocols use 200mcg per injection, also three times weekly. A 5mg vial yields 25 doses at 200mcg each, lasting approximately 8 weeks. This dosing asymmetry is why Ipamorelin drives more of the monthly cost despite having a lower per-vial price than CJC-1295 no DAC.
- Our experience working with research teams shows the reconstitution step is where most cost miscalculations occur. Researchers assume one bacteriostatic water bottle per peptide vial, but standard reconstitution uses 2mL of bacteriostatic water per 5mg vial. A 30mL bottle actually reconstitutes 15 vials, not one. That $12–$18 bottle spreads across multiple months if you're tracking it correctly. The miscalculation compounds when researchers discard partially used bacteriostatic water after 28 days due to peptide stability concerns, even though the solvent itself remains sterile for 6+ months if refrigerated correctly.